| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | 21.33% | — | — | — | — | — | — | — |
| Operating Margin | -40274.44% | — | -64098.77% | -3311.07% | -2182.17% | — | — | — | — | — | — | — |
| EBITDA Margin | -40082.22% | — | -63123.46% | -3243.20% | -2136.36% | — | — | — | — | — | — | — |
| Net Margin | -37652.22% | — | -60269.14% | -3205.53% | -2165.56% | — | — | — | — | — | — | — |
| Current Ratio | 6.20 | 9.14 | 9.21 | 10.44 | 11.66 | 13.62 | 1.89 | 2.36 | 3.82 | 4.95 | 5.74 | 0.78 |
| Quick Ratio | 6.20 | 9.14 | 9.21 | 10.44 | 11.66 | 13.62 | 1.89 | 2.36 | 3.82 | 4.95 | 5.74 | 0.78 |
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | — | — |
| ROE | -432.56% | -116.74% | -134.19% | -49.66% | -33.69% | -36.23% | -388.01% | -268.40% | -194.58% | -135.06% | -95.68% | 1284.12% |
| ROA | -65.45% | -49.73% | -59.94% | -28.91% | -30.82% | -33.46% | -187.65% | -158.86% | -145.07% | -107.96% | -79.08% | -326.16% |
| Asset Turnover | 0.00 | — | 0.00 | 0.01 | 0.01 | — | — | — | — | — | — | — |
| Book Value / Share | 0.25 | 1.09 | 1.37 | 2.75 | 3.58 | — | — | — | — | — | — | — |
Actinium Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing innovative targeted therapies for cancer. The company's primary aim is to harness the power of radioisotopes in conjunction with proprietary tumor-targeting agents to improve outcomes for patients with difficult-to-treat cancers. Actinium's flagship platform, Antibody Radiation-Conjugates (ARCs), is designed to deliver potent radiation directly to cancer cells, minimizing exposure to healthy tissues and enhancing the potency of therapeutic regimens. Operating in the highly competitive pharmaceutical sector, Actinium's research is concentrated on hematologic malignancies, including acute myeloid leukemia and myelodysplastic syndromes. The company plays a significant role in the niche of targeted radiotherapy, an area gaining traction for its promise in personalized medicine. Actinium Pharmaceuticals leverages collaborations with renowned research institutions to advance its pipeline and bring novel treatments to patients. Positioned at the intersection of oncology and radiopharmaceuticals, Actinium aims to set new standards in cancer treatment while addressing unmet medical needs."